AstraZeneca India gets DCGI permission for leukaemia drug

AstraZeneca Pharma India Limited announced that it has received import and marketing permission in form CT-20 from Drugs Controller General of India (DCGI) for Acalabrutinib 100 mg capsules (Calquence).

As a result, the receipt of this import and market permission has paved way for the launch of the company's Acalabrutinib 100 mg capsules (Calquence) in India, subject to related statutory approvals and licences. The drug indicated is used for the treatment of patients with Chronic Lymphocytic Leukaemia (CLL) and Small Lymphocytic Lymphoma (SLL).

AstraZeneca Pharma India Limited is a global biopharmaceutical company engaged in the discovery, development and commercialisation of medicines for core areas of healthcare, including cardiovascular disease, cancer and respiratory, inflammatory and autoimmune disease.

At 12.30 pm on Friday, the stock was trading at Rs 2,287.40, up by 1.39 per cent or Rs 31.25 per share. The 52-week high is recorded at Rs 2,940.45 and the 52-week low is Rs 1,635.30 on BSE.